CI Bio-Revolution Index ETF (TSX:CDNA)
Assets | 5.89M |
Expense Ratio | 0.72% |
PE Ratio | 28.87 |
Dividend (ttm) | 0.09 |
Dividend Yield | 0.58% |
Ex-Dividend Date | Mar 25, 2025 |
Payout Frequency | Quarterly |
Payout Ratio | n/a |
1-Year Return | -14.56% |
Volume | 1,600 |
Open | 15.44 |
Previous Close | 16.97 |
Day's Range | 15.44 - 15.44 |
52-Week Low | 14.60 |
52-Week High | 18.00 |
Beta | 1.39 |
Holdings | 67 |
Inception Date | Feb 24, 2022 |
About CDNA
CI Bio-Revolution Index ETF is an exchange traded fund launched and managed by CI Global Asset Management. The fund invests in public equity markets of global region. It invests in stocks of companies operating across healthcare, pharmaceuticals, biotechnology, life sciences and genomics sectors. The fund invests in growth and value stocks of companies across diversified market capitalization. It seeks to track the performance of the Solactive Global Genomics Immunology and Medical Revolution CAD Hedged Index NTR, by using full replication technique. CI Bio-Revolution Index ETF was formed on February 24, 2022 and is domiciled in Canada.
Performance
CDNA had a total return of -14.56% in the past year, including dividends. Since the fund's inception, the average annual return has been -9.82%.
Top 10 Holdings
228.87% of assetsName | Symbol | Weight |
---|---|---|
Canadian Dollar | n/a | 108.95% |
Us Dollar | n/a | 86.29% |
Swiss Franc | n/a | 8.61% |
Hong Kong Dollar | n/a | 4.26% |
Danish Kroner | n/a | 3.81% |
British Pound | n/a | 3.60% |
AbbVie Inc. | ABBV | 3.60% |
AstraZeneca PLC | AZN | 3.36% |
Bristol-Myers Squibb Company | BMY | 3.25% |
Vertex Pharmaceuticals Incorporated | VRTX | 3.16% |
Dividend History
Ex-Dividend | Amount | Pay Date |
---|---|---|
Mar 25, 2025 | 0.0255 CAD | Mar 31, 2025 |
Dec 23, 2024 | 0.0195 CAD | Dec 31, 2024 |
Sep 23, 2024 | 0.0222 CAD | Sep 27, 2024 |
Jun 24, 2024 | 0.023 CAD | Jun 28, 2024 |
Mar 21, 2024 | 0.0189 CAD | Mar 28, 2024 |
Dec 20, 2023 | 0.035 CAD | Dec 29, 2023 |